Company intelligence / Profile preview
EMD Serono
Rockland, Massachusetts, United Statesemdserono.com ↗
- Ownership
- Private
- Employees
- ~1000
- Development stage
- Commercial
01
Overview
EMD Serono has multiple commercial products and an expanding pipeline in neurology, oncology, immuno-oncology and immunology. Recent clinical developments include advancing M9140 (anti-CEACAM5 ADC) to Phase Ib in colorectal cancer, with plans to expand to other CEACAM5-expressing tumors, and preparing to enter first-in-human studies with M3554 (anti-GD2 ADC) in 2024.[9]
- Therapeutic areas
- Women's HealthOncologyNeurology
- Modalities
- Small moleculesbiologicsantibody-drug conjugates (ADCs)
- Industry
- Pharma
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on EMD Serono.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EMD Serono.